- Home
- GSIW vs KALA Comparison
GSIW vs KALA Comparison
Compare GSIW & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- KALA
- Stock Information
- Founded
- GSIW 2016
- KALA 2009
- Country
- GSIW Hong Kong
- KALA United States
- Employees
- GSIW N/A
- KALA N/A
- Industry
- GSIW
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- KALA Health Care
- Exchange
- GSIW Nasdaq
- KALA Nasdaq
- Market Cap
- GSIW 27.2M
- KALA 26.2M
- IPO Year
- GSIW 2023
- KALA 2017
- Fundamental
- Price
- GSIW $1.60
- KALA $5.82
- Analyst Decision
- GSIW
- KALA Strong Buy
- Analyst Count
- GSIW 0
- KALA 3
- Target Price
- GSIW N/A
- KALA $14.00
- AVG Volume (30 Days)
- GSIW 2.2M
- KALA 77.6K
- Earning Date
- GSIW 01-01-0001
- KALA 08-05-2025
- Dividend Yield
- GSIW N/A
- KALA N/A
- EPS Growth
- GSIW N/A
- KALA N/A
- EPS
- GSIW N/A
- KALA N/A
- Revenue
- GSIW $1,313,795.00
- KALA N/A
- Revenue This Year
- GSIW N/A
- KALA N/A
- Revenue Next Year
- GSIW N/A
- KALA N/A
- P/E Ratio
- GSIW N/A
- KALA N/A
- Revenue Growth
- GSIW N/A
- KALA N/A
- 52 Week Low
- GSIW $0.35
- KALA $2.92
- 52 Week High
- GSIW $12.30
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- GSIW 74.17
- KALA 66.64
- Support Level
- GSIW $1.48
- KALA $4.36
- Resistance Level
- GSIW $1.64
- KALA $5.75
- Average True Range (ATR)
- GSIW 0.13
- KALA 0.54
- MACD
- GSIW -0.02
- KALA 0.08
- Stochastic Oscillator
- GSIW 80.00
- KALA 82.44
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.